IXICO plc (GB:IXI) has released an update.
IXICO plc, a company specializing in precision analytics for neuroscience, reported a challenging H1 2024 with revenues of £2.5 million, a decrease from £3.2 million in the previous year, and a growing EBITDA loss due to market conditions and reduced capital markets funding. Despite a dip in the order book from £13.3 million to £12.7 million, the company has secured new contracts and expects a stronger H2, backed by £1.1 million in cost efficiencies and a solidified sales strategy focusing on its ‘Precision in Neuroscience’ approach.
For further insights into GB:IXI stock, check out TipRanks’ Stock Analysis page.
